.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Teva
Accenture
Deloitte
Cipla
Express Scripts
McKesson
US Department of Justice
Daiichi Sankyo
Fish and Richardson

Generated: December 17, 2017

DrugPatentWatch Database Preview

FARYDAK Drug Profile

« Back to Dashboard

When do Farydak patents expire, and when can generic versions of Farydak launch?

Farydak is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and ten patent family members in forty-six countries and ten supplementary protection certificates in eight countries.

The generic ingredient in FARYDAK is panobinostat lactate. One supplier is listed for this compound. Additional details are available on the panobinostat lactate profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-001Feb 23, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-003Feb 23, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-001Feb 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-001Feb 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-002Feb 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-003Feb 23, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-002Feb 23, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-003Feb 23, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-003Feb 23, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpFARYDAKpanobinostat lactateCAPSULE;ORAL205353-002Feb 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FARYDAK

Country Document Number Estimated Expiration
TunisiaSN08495► Subscribe
Japan2015164968► Subscribe
Argentina035057► Subscribe
European Patent Office2409967► Subscribe
Australia2001282129► Subscribe
Czech Republic302707► Subscribe
European Patent Office1318980► Subscribe
Austria376999► Subscribe
China104324025► Subscribe
South Korea20140142335► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FARYDAK

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00068Denmark► SubscribePRODUCT NAME: PANOBINOSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER PANOBINOSTATLAKTAT; REG. NO/DATE: EU/1/15/1023 20150901
0778Netherlands► SubscribePRODUCT NAME: PANOBINOSTAT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/15/1023 20150901
90070-7Sweden► SubscribePRODUCT NAME: PANOBINOSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALTTHEREOF; REG. NO/DATE: EU/1/15/1023 20150901
0160001 00181Estonia► SubscribePRODUCT NAME: PANOBINOSTAAT;REG NO/DATE: EU/1/15/1023 01.09.2015
2016003Lithuania► SubscribePRODUCT NAME: PANOBINOSTATAS; REGISTRATION NO/DATE: EU/1/15/1023 20120828
C0086France► SubscribePRODUCT NAME: PANOBINOSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1023 20150901
2016003,C1912640Lithuania► SubscribePRODUCT NAME: PANOBINOSTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1023 20120828
2015 00068Denmark► SubscribePRODUCT NAME: PANOBINOSTAT ELLER ET FARMACEUTISK SALT ELLER DERIVAT DERAF; REG. NO/DATE: EU/1/15/1023 20150901
890Luxembourg► SubscribePRODUCT NAME: PANOBINSTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE , OU UN DERIVE DE CELUI-CI (FARYDAK); FIRST REGISTRATION: 20150901
2015000098Germany► SubscribePRODUCT NAME: PANOBINOSTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER DERIVAT HIERVON; REGISTRATION NO/DATE: EU/1/15/1023 20150828
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Covington
Julphar
UBS
Boehringer Ingelheim
Citi
McKesson
US Department of Justice
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot